INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
September 07 2022 - 9:00AM
INmune Bio (NASDAQ: INMB), a clinical- stage immunology company
focused on developing treatments that harness the patient’s immune
system to fight disease, announced today that RJ Tesi, M.D., Chief
Executive Officer will present a corporate overview at the H.C.
Wainwright 24th Annual Global Investment Conference being held on
September 12 - 14, 2022, and the Baird Global Healthcare Conference
being held on September 13 – 14, 2022.
H. C. Wainwright Global Healthcare Conference
Presentation
Date: |
September 13,
2022 |
|
|
Time: |
4:00 pm ET |
|
|
Location: |
Lotte New York Palace,
Holmes II, 4th Floor |
Management will be available for one-on-one meetings. To request
a meeting and to register for the conference, click here:
https://hcwevents.com/annualconference/
Baird Global Healthcare Conference
Presentation
Date: |
September 14,
2022 |
|
|
Time: |
3:45 pm ET |
|
|
Location: |
InterContinental New
York Barclay |
Management will be available for one-on-one meetings. To request
a meeting and to register for the conference, click here:
https://www.meetmax.com/sched/event_86467/invitee_login.html
About INmune Bio, Inc.
INmuneBio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused
on developing treatments that target the innate immune system to
fight disease. INmune Bio has two product platforms that are both
in clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. DN-TNF
product candidates are in clinical trials to determine if they can
treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive
Impairment and treatment-resistant depression (XPro™). The Natural
Killer Cell Priming Platform includes INKmune™ developed to prime a
patient’s NK cells to eliminate minimal residual disease in
patients with cancer. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of
hematologic and solid tumor malignancies, and chronic inflammation.
To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact: David Moss, CFO
info@inmunebio.com(858) 964-3720 x-101
Investor Contact:Core
IRJason
Nelsoninfo@inmunebio.com516.842.9614 x-823.
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024